Royalty Pharma (RPRX) executive compensation, 2026 proxy

Pablo Legorreta, Chief Executive Officer, was paid $937,500 in 2025. The CEO-to-median-employee pay ratio was 4:1, on median employee pay of $349,893.

Filed
April 10, 2026
Annual meeting
June 4, 2026
Pay year
2025
Named executives
5
CEO total pay
$937,5002025
CEO to median employee
4:1median $349,893
Prior say-on-pay support
92%of votes cast
2025 Portfolio Receipts
$3.3BNFinancial highlights
2025 Capital Deployment
$2.6BNTransaction value
Internalization Approval
99.9%Shares voted
Say-on-Pay Support
92%2025 annual meeting

How Legorreta was paid

$937,500 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary100%

Named executive officers

ExecutiveTotal
Pablo LegorretaChief Executive Officer$937,500
Terrance CoyneExecutive Vice President & Chief Financial Officer$1,323,000
Christopher HiteExecutive Vice President & Vice Chairman$1,323,000
George LloydSenior Advisor; former Executive Vice President, Chief Legal Officer & Investments$1,323,000
Marshall Urist, M.D., Ph.D.Executive Vice President, Research & Investments$1,323,000

What changed and why

  • On May 16, 2025, the company completed the internalization of its formerly external manager into an integrated public company structure.
  • Following the internalization, named executive officers became company employees and received base salaries determined by the compensation committee.
  • $938KCEO Pablo Legorreta received a base salary of $937,500 and total compensation of $937,500 for fiscal year 2025 in the summary table.
  • $1.3MOther named executive officers each received base salaries and total compensation of $1,323,000 for the fiscal year ended December 31, 2025.
  • $350KThe CEO to median employee pay ratio for 2025 was approximately 4 to 1 based on median employee total compensation of $349,893.
  • 92%Shareholders demonstrated strong support with approximately 92% of votes cast approving the advisory say-on-pay resolution at the 2025 annual meeting.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.